Vancouver-based Borealis secured $150M in Series A funding, led by Versant Ventures and Novartis AG. The funds will enhance their RNA medicine development. Novartis also gains an option to acquire two future programs, potentially earning Borealis up to $750M through clinical and regulatory milestones.